DESTINY-Gastric03 is a phase Ib/II, dose-escalation, and dose-expansion study that evaluates trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations with chemotherapy or ±checkpoint inhibitor in patients with HER2-overexpressing gastric cancer. This evidence concerns the gene ERBB2 and gastric cancer.